BioSpace News Archive

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced its operating and financial results for the first quarter of 2020.

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, announced financial results for the first quarter ended March 31, 2020 and provided an update on its clinical development programs.

Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reports its financial results and corporate update for the first quarter ended March 31, 2020.

Cigna has taken bold actions throughout the COVID-19 pandemic to make it easier and more affordable for customers to access the care they need to fight the virus and prevent its spread.

Clinical response was associated with tumor-specific replication, PD-L1 upregulation, and CD8+ cell recruitment in multiple myeloma patients treated with pelareorep and carfilzomib

Galmed Pharmaceuticals Ltd. provides updated information on the Company’s clinical development program and reports financial results for the three months ended March 31, 2020.

Colorcon, a world leader in the development and supply of film coating systems and excipients, announces SoteriaRx™.

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received CE mark approval for the Senza® Omnia™ Spinal Cord Stimulation (SCS) system.

ALX Oncology Holdings Inc. , a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the Phase 1 study of ALX148 in patients with advanced solid tumors has been selected for presentation in the Poster Discussion Session at the Virtual 2020 ASCO Annual Meeting, May 29 – 31, 2020. Virtual ASCO 2020 Presentation Information Title: A Phase 1 study